Literature DB >> 6250760

Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.

A Ohlsson, J E Lindgren, A Wahlen, S Agurell, L E Hollister, H K Gillespie.   

Abstract

Delta-9-tetrahydrocannabinol (THC) was given intravenously, by smoking, and by mouth to 11 healthy subjects. Plasma profiles of THC after smoking and intravenous injection were similar whereas plasma levels after oral doses were low and irregular, indicating slow and erratic absorption. Based on AUC0-360 min systemic availability of THC after smoking was estimated to be 18 +/- 6%. Oral THC in a chocolate cookie provided systemic availability of 6 +/- 3%. Of the two major clinical signs of cannabis intoxication, reddened conjunctivae persisted for as long as THC levels were above 5 ng/ml, and tachycardia was a less reliable measurement of prevailing THC levels or "high." The time courses of plasma concentrations and clinical "high" were of the same order for intravenous injection and smoking, with prompt onset and steady decline over a 4-hr period. The appearance of "high" lagged behind the increase in plasma concentrations, suggesting that brain concentrations were increasing as plasma concentrations decreased. After oral THC, the onset of clinical effects was much slower and lasted longer, but effects occurred at much lower plasma concentrations than after the other two methods of administration.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6250760     DOI: 10.1038/clpt.1980.181

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  101 in total

1.  Comparative effects of pulmonary and parenteral Δ⁹-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats.

Authors:  Laurie A Manwell; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2014-11-15       Impact factor: 4.530

2.  Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; William D Darwin; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-06-08       Impact factor: 8.327

3.  Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.

Authors:  Erin L Karschner; W David Darwin; Robert S Goodwin; Stephen Wright; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-11-15       Impact factor: 8.327

4.  Human pharmacology of 1S and 1R enantiomers of delta-3-tetrahydrocannabinol.

Authors:  L E Hollister; H K Gillespie; R Mechoulam; M Srebnik
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Subjective and physiological effects after controlled Sativex and oral THC administration.

Authors:  E L Karschner; W D Darwin; R P McMahon; F Liu; S Wright; R S Goodwin; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

6.  Effects of oral Δ9-tetrahydrocannabinol on the cerebral processing of olfactory input in healthy non-addicted subjects.

Authors:  Carmen Walter; Bruno G Oertel; Lisa Felden; Ulrike Nöth; Johannes Vermehren; Ralf Deichmann; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2017-09-02       Impact factor: 2.953

Review 7.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Acute effects of marijuana smoking on aggressive, escape and point-maintained responding of male drug users.

Authors:  D R Cherek; J D Roache; M Egli; C Davis; R Spiga; K Cowan
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Effects of 20 mg oral Δ(9) -tetrahydrocannabinol on the olfactory function of healthy volunteers.

Authors:  Carmen Walter; Bruno G Oertel; Dagmar Ludyga; Alfred Ultsch; Thomas Hummel; Jörn Lötsch
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

Review 10.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.